Arrowhead Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Arrowhead Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 15.6% ve 11.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 14.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -84.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

15.6%

Kazanç büyüme oranı

14.62%

EPS büyüme oranı

Biotechs kazanç büyümesi	23.8%
Gelir büyüme oranı	11.3%
Gelecekteki özkaynak getirisi	-84.47%
Analist kapsamı	Good
Son güncelleme	23 Dec 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Dec 02

Arrowhead: Gains Make Mockery Of My Sell Call - But Jury May Still Be Out (Rating Upgrade)

Nov 27

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Oct 07

Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified

Aug 21

Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles

May 18 Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches.

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

May 14

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns

Feb 10

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 26

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:ARWR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2028	486	-417	-402	-388	10
9/30/2027	276	-573	-400	-384	12
9/30/2026	400	-443	-230	-210	14
9/30/2025	829	-2	157	180	N/A
6/30/2025	573	-148	-18	22	N/A
3/31/2025	545	-144	10	61	N/A
12/31/2024	3	-640	-572	-491	N/A
9/30/2024	4	-599	-604	-463	N/A
6/30/2024	20	-539	-533	-352	N/A
3/31/2024	35	-471	-470	-257	N/A
12/31/2023	182	-297	-403	-196	N/A
9/30/2023	241	-205	-331	-154	N/A
6/30/2023	256	-181	-342	-197	N/A
3/31/2023	273	-150	-353	-245	N/A
12/31/2022	278	-155	-236	-150	N/A
9/30/2022	243	-176	-189	-136	N/A
6/30/2022	250	-154	-120	-91	N/A
3/31/2022	263	-112	-75	-52	N/A
12/31/2021	144	-183	124	149	N/A
9/30/2021	138	-141	148	171	N/A
6/30/2021	108	-126	167	184	N/A
3/31/2021	89	-110	165	181	N/A
12/31/2020	80	-103	-123	-111	N/A
9/30/2020	88	-85	-108	-96	N/A
6/30/2020	124	-24	-89	-71	N/A
3/31/2020	139	10	-46	-27	N/A
12/31/2019	164	53	-34	-19	N/A
9/30/2019	169	68	161	173	N/A
6/30/2019	137	46	N/A	157	N/A
3/31/2019	95	10	N/A	132	N/A
12/31/2018	47	-29	N/A	136	N/A
9/30/2018	16	-54	N/A	-47	N/A
6/30/2018	14	-54	N/A	-54	N/A
3/31/2018	22	-44	N/A	-50	N/A
12/31/2017	31	-35	N/A	-49	N/A
9/30/2017	31	-34	N/A	-24	N/A
6/30/2017	23	-46	N/A	-25	N/A
3/31/2017	13	-60	N/A	-33	N/A
12/31/2016	4	-75	N/A	-33	N/A
9/30/2016	0	-82	N/A	-64	N/A
6/30/2016	0	-84	N/A	-66	N/A
3/31/2016	0	-81	N/A	-61	N/A
12/31/2015	0	-89	N/A	-63	N/A
9/30/2015	0	-92	N/A	-66	N/A
6/30/2015	0	-90	N/A	-65	N/A
3/31/2015	0	-85	N/A	-61	N/A
12/31/2014	0	-71	N/A	-53	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ARWR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: ARWR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: ARWR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: ARWR şirketinin gelirinin (yıllık 11.3% ) US pazarından (yıllık 10.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ARWR şirketinin gelirinin (yıllık 11.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ARWR 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/12/28 02:31
Gün Sonu Hisse Fiyatı	2025/12/26 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2025/09/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Arrowhead Pharmaceuticals, Inc. 27 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ying Huang	Barclays
William Pickering	Bernstein
Jason Matthew Gerberry	BofA Global Research

Arrowhead Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 7.4% to US$59.25

Consensus estimates of losses per share improve by 87%

Price target increased by 16% to US$55.00

Consensus EPS estimates fall by 221%

Consensus EPS estimates have been downgraded.

No longer forecast to breakeven

Recent updates

Chairman notifies of intention to sell stock

Chairman recently sold US$12m worth of stock

Chairman notifies of intention to sell stock

Now 20% overvalued after recent price rise

Independent Director recently sold US$992k worth of stock

Price target increased by 7.4% to US$59.25

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Independent Director recently sold US$493k worth of stock

Arrowhead Pharmaceuticals, Inc. Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Independent Director notifies of intention to sell stock

Arrowhead: Gains Make Mockery Of My Sell Call - But Jury May Still Be Out (Rating Upgrade)

New minor risk - Share price stability

Consensus estimates of losses per share improve by 87%

Price target increased by 16% to US$55.00

Arrowhead Pharmaceuticals, Inc Announces FDA Approval of Redemplo (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Consensus EPS estimates fall by 221%

Arrowhead Pharmaceuticals, Inc. Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Files Complaint for Patent Infringement Against Arrowhead Pharmaceuticals, Inc

Consensus EPS estimates have been downgraded.

Arrowhead Pharmaceuticals, Inc. Requests Regulatory Clearance to Initiate Phase 1/2A Study of Aro-Mapt for the Treatment of Alzheimer's Disease and Other Tauopathies

No longer forecast to breakeven

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Consensus EPS estimates fall by 65%

Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified

Consensus EPS estimates fall from profit to US$0.11 loss, revenue upgraded

No longer forecast to breakeven

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Forecast to breakeven in 2025

Arrowhead Pharmaceuticals Completes Enrollment in Shasta-3, Shasta-4, and Muir-3 Phase 3 Studies of Plozasiran

Consensus EPS estimates increase by 17%

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of Aro-Alk7 for the Treatment of Obesity

Insufficient new directors

Consensus EPS estimates increase by 168%

Forecast to breakeven in 2025

Consensus revenue estimates increase by 112%

Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

New major risk - Revenue and earnings growth

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective May 13, 2025

Chairman recently sold US$1.5m worth of stock

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Is Finally Arriving

Chairman recently sold US$775k worth of stock

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals, Inc. Presents Preclinical Data on Aro-Alk7 for Treatment of Obesity

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns

Arrowhead Pharmaceuticals, Inc. Appoints Douglas Ingram as Director

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2025

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

CEO, President & Director recently sold US$567k worth of stock

CEO, President & Director notifies of intention to sell stock

Consensus revenue estimates increase by 12%

Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Consensus revenue estimates increase by 66%

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity